Loading…
Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation
Saved in:
| Published in: | Leukemia 2020-02, Vol.34 (2), p.651-655 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c450t-a9d60ebf9b125dc1046996675b1a2490cb50a3643fc030bdc0629d66540cd2f63 |
| container_end_page | 655 |
| container_issue | 2 |
| container_start_page | 651 |
| container_title | Leukemia |
| container_volume | 34 |
| creator | Kint, Nicolas G. Heylen, Elien Pepe, Daniele De Keersmaecker, Kim Verfaillie, Catherine M. Delforge, Michel |
| description | |
| doi_str_mv | 10.1038/s41375-019-0565-y |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2283107961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A612927079</galeid><sourcerecordid>A612927079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-a9d60ebf9b125dc1046996675b1a2490cb50a3643fc030bdc0629d66540cd2f63</originalsourceid><addsrcrecordid>eNp9kkuLFTEQhRtRnOvoD3AjDYK46bGSzqOzHC6-YMCNrkM6nZ6bIelc80DaX2-aOzqOqGSRQH2nilM5TfMcwQWCfniTCOo57QCJDiij3fqg2SHCWUcpRQ-bHQwD75jA5Kx5ktINwFZkj5uzHhHGCR52zbpXcbbue_B27OwyFW2mNppsdXFBrzkkm1q7tEeVrVlyar_ZfGh9cdkenWn9alzwqq2QViVV7bi21h-VjfWdTfR2Ua41cc2HGOzUepVLrL3C8rR5NCuXzLPb-7z58u7t5_2H7urT-4_7y6tOEwq5U2JiYMZZjAjTSSMgTAjGOB2RwkSAHimonpF-1tDDOGlguEoYJaAnPLP-vHl96nuM4WsxKUtvkzbOqcWEkiTGQ4-AC4Yq-vIP9CaUWA1UinAKIDjj_6V6IhAnHIY76lo5I-0yhxyV3kbLS4awwLzOrNTFX6h6JuOtDoupf2PuC179JjgY5fIhBVe2jab7IDqBOoaUopnlMVqv4ioRyC098pQeWdMjt_TItWpe3DorozfTL8XPuFQAn4BUS8u1iXfW_931B7ttzvc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2349174708</pqid></control><display><type>article</type><title>Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation</title><source>LexisNexis - News & Business</source><source>Springer Link</source><creator>Kint, Nicolas G. ; Heylen, Elien ; Pepe, Daniele ; De Keersmaecker, Kim ; Verfaillie, Catherine M. ; Delforge, Michel</creator><creatorcontrib>Kint, Nicolas G. ; Heylen, Elien ; Pepe, Daniele ; De Keersmaecker, Kim ; Verfaillie, Catherine M. ; Delforge, Michel</creatorcontrib><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/s41375-019-0565-y</identifier><identifier>PMID: 31467428</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/31 ; 14/1 ; 14/63 ; 38/77 ; 3T3 Cells ; 631/67/1990/804 ; 692/699/1541/1990/804 ; 82/29 ; 82/58 ; Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer Research ; Carfilzomib ; Complications and side effects ; Critical Care Medicine ; Drug therapy ; Erythrocytes ; Erythroid Cells - drug effects ; Female ; Health aspects ; Hematology ; Hemolytic anemia ; Humans ; Intensive ; Internal Medicine ; Letter ; Male ; Medicine ; Medicine & Public Health ; Mice ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Oligopeptides - therapeutic use ; Oncology ; Physiological aspects ; Proteasome Inhibitors - therapeutic use ; Reticulocytosis - drug effects ; Retrospective Studies ; Risk factors ; Ubiquitin-proteasome system</subject><ispartof>Leukemia, 2020-02, Vol.34 (2), p.651-655</ispartof><rights>Springer Nature Limited 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>2019© Springer Nature Limited 2019</rights><rights>Springer Nature Limited 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c450t-a9d60ebf9b125dc1046996675b1a2490cb50a3643fc030bdc0629d66540cd2f63</cites><orcidid>0000-0002-7420-9531</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31467428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kint, Nicolas G.</creatorcontrib><creatorcontrib>Heylen, Elien</creatorcontrib><creatorcontrib>Pepe, Daniele</creatorcontrib><creatorcontrib>De Keersmaecker, Kim</creatorcontrib><creatorcontrib>Verfaillie, Catherine M.</creatorcontrib><creatorcontrib>Delforge, Michel</creatorcontrib><title>Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><subject>13/31</subject><subject>14/1</subject><subject>14/63</subject><subject>38/77</subject><subject>3T3 Cells</subject><subject>631/67/1990/804</subject><subject>692/699/1541/1990/804</subject><subject>82/29</subject><subject>82/58</subject><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer Research</subject><subject>Carfilzomib</subject><subject>Complications and side effects</subject><subject>Critical Care Medicine</subject><subject>Drug therapy</subject><subject>Erythrocytes</subject><subject>Erythroid Cells - drug effects</subject><subject>Female</subject><subject>Health aspects</subject><subject>Hematology</subject><subject>Hemolytic anemia</subject><subject>Humans</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Letter</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mice</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Oligopeptides - therapeutic use</subject><subject>Oncology</subject><subject>Physiological aspects</subject><subject>Proteasome Inhibitors - therapeutic use</subject><subject>Reticulocytosis - drug effects</subject><subject>Retrospective Studies</subject><subject>Risk factors</subject><subject>Ubiquitin-proteasome system</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kkuLFTEQhRtRnOvoD3AjDYK46bGSzqOzHC6-YMCNrkM6nZ6bIelc80DaX2-aOzqOqGSRQH2nilM5TfMcwQWCfniTCOo57QCJDiij3fqg2SHCWUcpRQ-bHQwD75jA5Kx5ktINwFZkj5uzHhHGCR52zbpXcbbue_B27OwyFW2mNppsdXFBrzkkm1q7tEeVrVlyar_ZfGh9cdkenWn9alzwqq2QViVV7bi21h-VjfWdTfR2Ua41cc2HGOzUepVLrL3C8rR5NCuXzLPb-7z58u7t5_2H7urT-4_7y6tOEwq5U2JiYMZZjAjTSSMgTAjGOB2RwkSAHimonpF-1tDDOGlguEoYJaAnPLP-vHl96nuM4WsxKUtvkzbOqcWEkiTGQ4-AC4Yq-vIP9CaUWA1UinAKIDjj_6V6IhAnHIY76lo5I-0yhxyV3kbLS4awwLzOrNTFX6h6JuOtDoupf2PuC179JjgY5fIhBVe2jab7IDqBOoaUopnlMVqv4ioRyC098pQeWdMjt_TItWpe3DorozfTL8XPuFQAn4BUS8u1iXfW_931B7ttzvc</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Kint, Nicolas G.</creator><creator>Heylen, Elien</creator><creator>Pepe, Daniele</creator><creator>De Keersmaecker, Kim</creator><creator>Verfaillie, Catherine M.</creator><creator>Delforge, Michel</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7420-9531</orcidid></search><sort><creationdate>20200201</creationdate><title>Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation</title><author>Kint, Nicolas G. ; Heylen, Elien ; Pepe, Daniele ; De Keersmaecker, Kim ; Verfaillie, Catherine M. ; Delforge, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-a9d60ebf9b125dc1046996675b1a2490cb50a3643fc030bdc0629d66540cd2f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>13/31</topic><topic>14/1</topic><topic>14/63</topic><topic>38/77</topic><topic>3T3 Cells</topic><topic>631/67/1990/804</topic><topic>692/699/1541/1990/804</topic><topic>82/29</topic><topic>82/58</topic><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer Research</topic><topic>Carfilzomib</topic><topic>Complications and side effects</topic><topic>Critical Care Medicine</topic><topic>Drug therapy</topic><topic>Erythrocytes</topic><topic>Erythroid Cells - drug effects</topic><topic>Female</topic><topic>Health aspects</topic><topic>Hematology</topic><topic>Hemolytic anemia</topic><topic>Humans</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Letter</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mice</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Oligopeptides - therapeutic use</topic><topic>Oncology</topic><topic>Physiological aspects</topic><topic>Proteasome Inhibitors - therapeutic use</topic><topic>Reticulocytosis - drug effects</topic><topic>Retrospective Studies</topic><topic>Risk factors</topic><topic>Ubiquitin-proteasome system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kint, Nicolas G.</creatorcontrib><creatorcontrib>Heylen, Elien</creatorcontrib><creatorcontrib>Pepe, Daniele</creatorcontrib><creatorcontrib>De Keersmaecker, Kim</creatorcontrib><creatorcontrib>Verfaillie, Catherine M.</creatorcontrib><creatorcontrib>Delforge, Michel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kint, Nicolas G.</au><au>Heylen, Elien</au><au>Pepe, Daniele</au><au>De Keersmaecker, Kim</au><au>Verfaillie, Catherine M.</au><au>Delforge, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>34</volume><issue>2</issue><spage>651</spage><epage>655</epage><pages>651-655</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>31467428</pmid><doi>10.1038/s41375-019-0565-y</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-7420-9531</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2020-02, Vol.34 (2), p.651-655 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2283107961 |
| source | LexisNexis - News & Business; Springer Link |
| subjects | 13/31 14/1 14/63 38/77 3T3 Cells 631/67/1990/804 692/699/1541/1990/804 82/29 82/58 Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Carfilzomib Complications and side effects Critical Care Medicine Drug therapy Erythrocytes Erythroid Cells - drug effects Female Health aspects Hematology Hemolytic anemia Humans Intensive Internal Medicine Letter Male Medicine Medicine & Public Health Mice Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Oligopeptides - therapeutic use Oncology Physiological aspects Proteasome Inhibitors - therapeutic use Reticulocytosis - drug effects Retrospective Studies Risk factors Ubiquitin-proteasome system |
| title | Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A53%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carfilzomib-induced%20reticulocytosis%20in%20patients%20with%20multiple%20myeloma%20is%20caused%20by%20impaired%20terminal%20erythroid%20maturation&rft.jtitle=Leukemia&rft.au=Kint,%20Nicolas%20G.&rft.date=2020-02-01&rft.volume=34&rft.issue=2&rft.spage=651&rft.epage=655&rft.pages=651-655&rft.issn=0887-6924&rft.eissn=1476-5551&rft_id=info:doi/10.1038/s41375-019-0565-y&rft_dat=%3Cgale_proqu%3EA612927079%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-a9d60ebf9b125dc1046996675b1a2490cb50a3643fc030bdc0629d66540cd2f63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2349174708&rft_id=info:pmid/31467428&rft_galeid=A612927079&rfr_iscdi=true |